Concepedia

David Beer

DB

34

Publications

2.7K

Citations

23

H-Index

1996

Active since

Affiliations

Novartis (Singapore)(Current)

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

Novartis (United States)

Genomics Institute of the Novartis Research Foundation

David Beer is an author at Novartis (Singapore) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

1996–2021

34

Publications

34

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

Kévin Pethe, Patrícia Carvalho de Sequeira, Sanjay Agarwalla et al. · Nature Communications · 2010 · 303 citations · Full text

, , +24

Functional Profiling of Recombinant NS3 Proteases from All Four Serotypes of Dengue Virus Using Tetrapeptide and Octapeptide Substrate Libraries

Jun Li, Siew Pheng Lim, David Beer et al. · Journal of Biological Chemistry · 2005 · 246 citations · Full text

The Natural Product Cyclomarin Kills Mycobacterium Tuberculosis by Targeting the ClpC1 Subunit of the Caseinolytic Protease

E. Schmitt, Meliana Riwanto, Vasan K. Sambandamurthy et al. · Angewandte Chemie International Edition · 2011 · 195 citations

Peptide inhibitors of dengue virus NS3 protease. Part 1: Warhead

Zheng Yin, Sejal Patel, Weiling Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 157 citations · Full text

, , +5

Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors

Zheng Yin, Sejal Patel, Weiling Wang et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 152 citations · Full text

, , +9

Rows per page

1–5 of 34